Literature DB >> 14604725

Infectious keratitis after laser in situ keratomileusis: results of an ASCRS survey.

Renée Solomon1, Eric D Donnenfeld, Dimitri T Azar, Edward J Holland, F Rick Palmon, Stephen C Pflugfelder, Jonathan B Rubenstein.   

Abstract

To investigate the incidence, culture results, treatment, and visual outcomes of infectious keratitis after laser in situ keratomileusis (LASIK) worldwide, the Cornea Clinical Committee of the American Society of Cataract and Refractive Surgery (ASCRS) contacted 8600 United States and international ASCRS members by e-mail and asked them to respond to a questionnaire about post-LASIK infectious keratitis. One hundred sixteen infections were reported by 56 LASIK surgeons who had performed an estimated 338 550 procedures. Seventy-six cases presented in the first week after surgery, 7 during the second week, 17 between the second and fourth weeks, and 16 after 1 month. Forty-seven cases were not diagnosed on initial presentation. The most common organisms cultured were atypical mycobacteria and staphylococci. Empiric therapy is not recommended as most of the organisms are opportunistic and not responsive to conventional therapy. Flap elevation and culturing should be performed when post-LASIK infectious keratitis is suspected.

Entities:  

Mesh:

Year:  2003        PMID: 14604725     DOI: 10.1016/s0886-3350(03)00512-1

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  16 in total

1.  Intraoperative and early postoperative flap-related complications of laser in situ keratomileusis using two types of Moria microkeratomes.

Authors:  Yunus Karabela; Orkun Muftuoglu; Ibrahim Gokhan Gulkilik; Mehmet Selim Kocabora; Mustafa Ozsutcu
Journal:  Int Ophthalmol       Date:  2014-02-17       Impact factor: 2.031

2.  Very late-onset flap margin corneal ulcer following laser in situ keratomileusis.

Authors:  Gilad Rabina; Nur Azem; Michael Mimouni; Idan Hecht; David Varssano
Journal:  Int Ophthalmol       Date:  2019-04-13       Impact factor: 2.031

3.  Efficacy and tolerability of a fixed-dose moxifloxacin - dexamethasone formulation for topical prophylaxis in LASIK: a comparative, double-masked clinical trial.

Authors:  Mauro Campos; Mariana Avila; Anelise Wallau; Cristina Muccioli; Ana Luisa Höfling-Lima; Rubens Belfort
Journal:  Clin Ophthalmol       Date:  2008-06

4.  A rare devastating complication of LASIK: bilateral fungal keratitis.

Authors:  H Taylan Sekeroglu; E Erdem; K Yar; M Yağmur; T R Ersoz; A Uguz
Journal:  J Ophthalmol       Date:  2010-11-11       Impact factor: 1.909

Review 5.  LASIK interface complications: etiology, management, and outcomes.

Authors:  J Bradley Randleman; Rupa D Shah
Journal:  J Refract Surg       Date:  2012-08       Impact factor: 3.573

Review 6.  Nontuberculous Mycobacterial Ocular Infections: A Systematic Review of the Literature.

Authors:  Wajiha J Kheir; Huda Sheheitli; Maamoun Abdul Fattah; Rola N Hamam
Journal:  Biomed Res Int       Date:  2015-05-27       Impact factor: 3.411

7.  Management of severe Acanthamoeba keratitis and complicated cataract following laser in situ keratomileusis.

Authors:  N V Annapurna; Bhupesh Bagga; Prashant Garg; Joveeta Joseph; Savitri Sharma; Paavan Kalra; Ruchi Mittal
Journal:  Indian J Ophthalmol       Date:  2020-03       Impact factor: 1.848

8.  A case of intractable infectious keratitis and subsequent flap necrosis after laser in situ keratomileusis.

Authors:  Kazutaka Kamiya; Masayuki Kasahara; Kimiya Shimizu
Journal:  Clin Ophthalmol       Date:  2009-09-24

9.  Distinguishing infective versus noninfective keratitis.

Authors:  M Srinivasan; Jeena Mascarenhas; C N Prashanth
Journal:  Indian J Ophthalmol       Date:  2008 May-Jun       Impact factor: 1.848

10.  Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients.

Authors:  Steven A Nielsen; Marguerite B McDonald; Parag A Majmudar
Journal:  Clin Ophthalmol       Date:  2013-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.